Search Results - "Bilen, MA"

EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective by Wallace, JF, Adair, N, Perez, JR, Hall, T, Bilen, MA, Sussman, M

Get full text

The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma by Bilen, Mehmet Asim, Carlisle, Jennifer W, Sonpavde, Guru

“…Although significant advances have been made in the treatment of advanced renal cell carcinoma (RCC), patients still develop resistance to standard therapies…”
Get more information

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race by Bilen, Mehmet Asim, Khilfeh, Ibrahim, Rossi, Carmine, Muser, Erik, Morrison, Laura, Hilts, Annalise, Diaz, Lilian, Lefebvre, Patrick, Pilon, Dominic, George, Daniel J

“…Alterations in DNA damage repair genes in advanced prostate cancer (PC) may impact responses to therapy and clinical outcomes. This study described homologous…”
Get full text